Skip to Main Content

National Coverage Analysis (NCA) for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066N)

Expand/collapse the Contacts section

Contact(s)

Stuart Caplan

stuart.caplan@cms.hhs.gov

410-786-8564

Back to Top

Expand/collapse the Documents section

Documents

Tracking Sheet

Decision Memo

Back to Top

Expand/collapse the History of Considerations section

History of Considerations

Original Consideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (this document)

First reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R)

Second reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R2)

Third reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R3)

Fourth reconsideration for Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration (CAG-00066R4)

Back to Top

Footer Links

www